Literature DB >> 15723172

New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A.

J Briolat1, S D Wu, S K Mahata, B Gonthier, D Bagnard, S Chasserot-Golaz, K B Helle, D Aunis, M H Metz-Boutigue.   

Abstract

Catestatin (bCGA(344-364)), an endogenous peptide of bovine chromogranin A, was initially characterized for its effect on the inhibition of catecholamine release from chromaffin cells. Catestatin and its active domain (bCGA(344-358)) were identified in chromaffin cells and in secretion medium. The present study identified a potent antimicrobial activity of bCGA(344-358) in the lowmicromolar range against bacteria, fungi and yeasts, without showing any haemolytic activity. Confocal laser microscopy demonstrated penetration of the rhodaminated peptide into the cell membranes of fungi and yeasts and its intracellular accumulation. Time-lapse videomicroscopy showed arrest of fungal growth upon penetration of the labelled peptide into a fungal filament. We identified several catestatin-containing fragments in the stimulated secretion medium of human polymorphonuclear neutrophils, suggesting the N-terminal sequence of catestatin (bCGA(344-358)) (named cateslytin) as a novel component of innate immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723172     DOI: 10.1007/s00018-004-4461-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  25 in total

1.  The revised EuroSCORE II for the prediction of mortality in patients undergoing transcatheter aortic valve implantation.

Authors:  Alexander Sedaghat; Jan-Malte Sinning; Mariuca Vasa-Nicotera; Alexander Ghanem; Christoph Hammerstingl; Eberhard Grube; Georg Nickenig; Nikos Werner
Journal:  Clin Res Cardiol       Date:  2013-07-23       Impact factor: 5.460

2.  Transcatheter versus surgical aortic-valve replacement in high-risk patients.

Authors:  Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  EuroSCORE performance in valve surgery: a meta-analysis.

Authors:  Alessandro Parolari; Lorenzo L Pesce; Matteo Trezzi; Laura Cavallotti; Samer Kassem; Claudia Loardi; Davide Pacini; Elena Tremoli; Francesco Alamanni
Journal:  Ann Thorac Surg       Date:  2010-03       Impact factor: 4.330

4.  5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial.

Authors:  Samir R Kapadia; Martin B Leon; Raj R Makkar; E Murat Tuzcu; Lars G Svensson; Susheel Kodali; John G Webb; Michael J Mack; Pamela S Douglas; Vinod H Thourani; Vasilis C Babaliaros; Howard C Herrmann; Wilson Y Szeto; Augusto D Pichard; Mathew R Williams; Gregory P Fontana; D Craig Miller; William N Anderson; Jodi J Akin; Michael J Davidson; Craig R Smith
Journal:  Lancet       Date:  2015-03-15       Impact factor: 79.321

5.  Transcatheter aortic-valve replacement with a self-expanding prosthesis.

Authors:  David H Adams; Jeffrey J Popma; Michael J Reardon; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Maurice Buchbinder; James Hermiller; Neal S Kleiman; Stan Chetcuti; John Heiser; William Merhi; George Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John Conte; Brijeshwar Maini; Mubashir Mumtaz; Sharla Chenoweth; Jae K Oh
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

6.  ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease.

Authors:  Raphael Rosenhek; Bernard Iung; Pilar Tornos; Manuel J Antunes; Bernard D Prendergast; Catherine M Otto; Arie Pieter Kappetein; Janina Stepinska; Jens J Kaden; Christoph K Naber; Esmeray Acartürk; Christa Gohlke-Bärwolf
Journal:  Eur Heart J       Date:  2011-03-15       Impact factor: 29.983

7.  EuroSCORE overestimates the risk of cardiac surgery: results from the national registry of the German Society of Thoracic and Cardiovascular Surgery.

Authors:  J F Gummert; A Funkat; B Osswald; A Beckmann; W Schiller; A Krian; F Beyersdorf; A Haverich; J Cremer
Journal:  Clin Res Cardiol       Date:  2009-03-05       Impact factor: 5.460

8.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.

Authors:  Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

9.  Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.

Authors:  Eberhard Grube; Gerhard Schuler; Lutz Buellesfeld; Ulrich Gerckens; Axel Linke; Peter Wenaweser; Barthel Sauren; Friedrich-Wilhelm Mohr; Thomas Walther; Bernfried Zickmann; Stein Iversen; Thomas Felderhoff; Raymond Cartier; Raoul Bonan
Journal:  J Am Coll Cardiol       Date:  2007-06-06       Impact factor: 24.094

10.  The German Aortic Valve Registry (GARY): in-hospital outcome.

Authors:  Christian W Hamm; Helge Möllmann; David Holzhey; Andreas Beckmann; Christof Veit; Hans-Reiner Figulla; J Cremer; Karl-Heinz Kuck; Rüdiger Lange; Ralf Zahn; Stefan Sack; Gerhard Schuler; Thomas Walther; Friedhelm Beyersdorf; Michael Böhm; Gerd Heusch; Anne-Kathrin Funkat; Thomas Meinertz; Till Neumann; Konstantinos Papoutsis; Steffen Schneider; Armin Welz; Friedrich W Mohr
Journal:  Eur Heart J       Date:  2013-09-10       Impact factor: 29.983

View more
  43 in total

Review 1.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

2.  Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling.

Authors:  Gautam K Bandyopadhyay; Christine U Vu; Stefano Gentile; Howon Lee; Nilima Biswas; Nai-Wen Chi; Daniel T O'Connor; Sushil K Mahata
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

3.  Pore formation induced by an antimicrobial peptide: electrostatic effects.

Authors:  Frantz Jean-François; Juan Elezgaray; Pascal Berson; Pierre Vacher; Erick J Dufourc
Journal:  Biophys J       Date:  2008-09-26       Impact factor: 4.033

Review 4.  Cholinergic regulation of keratinocyte innate immunity and permeability barrier integrity: new perspectives in epidermal immunity and disease.

Authors:  Brenda J Curtis; Katherine A Radek
Journal:  J Invest Dermatol       Date:  2011-09-15       Impact factor: 8.551

5.  Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.

Authors:  Nitish R Mahapatra; Daniel T O'Connor; Sucheta M Vaingankar; Amiya P Sinha Hikim; Manjula Mahata; Saugata Ray; Eugenie Staite; Hongjiang Wu; Yusu Gu; Nancy Dalton; Brian P Kennedy; Michael G Ziegler; John Ross; Sushil K Mahata
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

Review 6.  Chromogranins: from discovery to current times.

Authors:  Karen B Helle; Marie-Helene Metz-Boutigue; Maria Carmela Cerra; Tommaso Angelone
Journal:  Pflugers Arch       Date:  2017-09-05       Impact factor: 3.657

7.  Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart.

Authors:  Bhawanjit K Brar; Erik Helgeland; Sushil K Mahata; Kuixing Zhang; Daniel T O'Connor; Karen B Helle; Anne K Jonassen
Journal:  Regul Pept       Date:  2010-07-22

8.  Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis.

Authors:  Michael Wagner; Mats Stridsberg; Christer G B Peterson; Per Sangfelt; Maria Lampinen; Marie Carlson
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

Review 9.  Chromogranin A: a novel susceptibility gene for essential hypertension.

Authors:  Bhavani S Sahu; Parshuram J Sonawane; Nitish R Mahapatra
Journal:  Cell Mol Life Sci       Date:  2009-11-27       Impact factor: 9.261

10.  Catestatin, an endogenous chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum.

Authors:  Aziza Akaddar; Cécile Doderer-Lang; Melissa R Marzahn; François Delalande; Marc Mousli; Karen Helle; Alain Van Dorsselaer; Dominique Aunis; Ben M Dunn; Marie-Hélène Metz-Boutigue; Ermanno Candolfi
Journal:  Cell Mol Life Sci       Date:  2009-12-31       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.